- 5 days ago
- 11 min read
If you or someone you love has just heard the words "CAR-T therapy" from a haematologist, you're probably holding two feelings at once: hope, because this treatment has put blood cancers into remission when nothing else worked — and dread, because the price tag and waitlists can feel overwhelming.
You're not alone in this. A growing number of Singaporean families are asking the same question: should we pursue CAR-T treatment in Singapore, or is it worth looking at CAR-T therapy in China instead?
This guide breaks down both paths honestly — what's approved, what it costs, what the process looks like, and the practical trade-offs — so you can have an informed conversation with your medical team rather than making a decision under pressure.
This article is for informational purposes only and is not medical or financial advice. Always consult your treating haematologist and a licensed financial advisor before making treatment decisions.
What Is CAR-T Therapy, in Plain Language?
CAR-T (Chimeric Antigen Receptor T-cell) therapy takes a patient's own immune cells, re-engineers them in a lab to recognise cancer cells, multiplies them, and infuses them back into the body as a "living drug."
Unlike chemotherapy, which is a repeated course, CAR-T is typically a one-time infusion. For certain relapsed or treatment-resistant blood cancers, it has produced complete remissions in patients who had run out of standard options.
It's currently approved for specific blood cancers only — not solid tumours like breast, lung, or colon cancer — though clinical trials for solid tumours are actively underway in several countries, including China.
CAR-T Treatment in Singapore: The Current Landscape
Singapore was the first country in Southeast Asia to bring commercial CAR-T therapy to patients, and it remains the region's most established hub for the treatment.
Which CAR-T Therapies Are Approved in Singapore
Singapore's Health Sciences Authority (HSA) approved <cite index="9-1">Kymriah (tisagenlecleucel) in March 2021 as the first commercially approved CAR-T therapy in the country</cite>, cleared for two indications:
Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have failed at least two prior lines of treatment
Children and young adults up to age 25 with relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL)
Yescarta (axicabtagene ciloleucel) followed with approval for third-line DLBCL treatment, and Singapore General Hospital has since built out both commercial and academic CAR-T programs, including in-house manufacturing capabilities for CD19 and dual-construct CAR-T products.
Yescarta vs. Kymriah vs. Carvykti and other alternatives : Which CAR T Therapy Is Best for Your Cancer?
Where to Get CAR-T Treatment in Singapore
The main centres currently offering CAR-T treatment in Singapore include:
Singapore General Hospital (SGH) — the first operational Kymriah treatment centre in Southeast Asia, now running both commercial CAR-T and an academic CAR-T program under its Hematopoietic Cell Therapy and Transplant Program
National University Hospital (NUH) — part of ongoing efforts to expand access for adult and paediatric patients
National Cancer Centre Singapore (NCCS) — closely integrated with SGH's cell therapy centre for lymphoma and leukaemia care
Private options, including Farrer Park Hospital's oncology programs, also serve patients — particularly international patients seeking CAR-T-adjacent care and support services.
The Real Cost of CAR-T Treatment in Singapore
This is where many Singaporean families hit a wall. Reported figures for CAR-T treatment in Singapore commonly sit in the US$200,000–300,000 range for the full treatment course, once you include cell collection, manufacturing, hospitalisation, and monitoring. Insurance coverage is inconsistent — some insurers cover it under critical illness or cancer riders, but many patients discover gaps only when they file a claim.
That gap between "approved and available" and "affordable for an average household" is exactly why some patients start looking beyond Singapore's borders.
Why Some Singaporean Patients Are Looking at CAR-T Therapy in China
China has moved fast in cellular therapy over the past five years. As of 2026, China's National Medical Products Administration (NMPA) has approved multiple domestic and licensed CAR-T products, and the country now operates dozens of CAR-T programs across major cities — a scale that has made it a serious option for international patients, not just a fallback.
China's Regulatory and Manufacturing Advantage
Several factors explain why China can offer CAR-T therapy at a noticeably lower price than Singapore or the US:
Domestic manufacturing — Chinese biotech firms produce CAR-T cells locally, avoiding the cross-continental shipping and logistics costs that inflate Western pricing
Faster cell production platforms — some Chinese centres use accelerated manufacturing technology that compresses production from the standard several weeks down to days, which can matter for aggressive, fast-progressing cancers
Investigator-Initiated Trials (IITs) — regulated by China's National Health Commission, these trials can allow eligible international patients to access CAR-T cells at little or no product cost, with patients covering only hospitalisation and diagnostic fees
Government-supported pricing and competition among a large number of treatment centres
Doctor discussing CAR-T treatment Singapore options with patient during consultation.
Top Hospitals in China for International CAR-T Patients
Hospitals with established international patient programs for CAR-T therapy include:
Peking Union Medical College Hospital (PUMCH), Beijing — dedicated international patient support, strong hematology-oncology integration
Fudan University Shanghai Cancer Center, and Shanghai Ruijin Hospital — high international CAR-T volume
Peking University Cancer Hospital, Beijing — specialised lymphoma and CAR-T program, including solid tumour trials
Beijing GoBroad Boren Hospital — high-volume dual-target CAR-T (CD19+CD22) for leukaemia and lymphoma
Sichuan University West China Hospital, Chengdu
What CAR-T Costs in China
Cost estimates vary depending on the source and treatment pathway, but a reasonable working range for commercial CAR-T therapy in China for international patients is roughly US$80,000–170,000 for the full treatment course, including hospitalisation and monitoring — while clinical trial pathways can bring costs down to roughly US$40,000–60,000 for eligible patients, since the cell product itself may be provided by the trial sponsor.
Compare that to Singapore's roughly US$200,000–300,000, or the US, where drug cost alone can exceed US$450,000 before hospital fees. Even accounting for flights, accommodation, and a multi-week stay, the total cost of care in China can still land meaningfully below what patients pay for the same category of treatment in Singapore.
A note of caution: published cost ranges across different medical-travel platforms vary quite a bit — some cite figures as low as US$30,000, others closer to US$275,000, depending on whether they're describing a clinical trial, a commercial product, or a bundled package. Always request a written, itemised quote directly from the hospital's international patient office before assuming any figure applies to your case.
CAR-T in China vs Singapore: Side-by-Side Comparison
Factor | Singapore | China |
Regulatory approval | HSA-approved commercial products (Kymriah, Yescarta) | NMPA-approved domestic and licensed products; some access via clinical trials |
Estimated total cost | ~US$200,000–300,000 | ~US$80,000–170,000 commercial; ~US$40,000–60,000 via eligible trials |
Manufacturing time | Standard 3–6 week "vein-to-vein" timeline | As fast as days to ~2–3 weeks at leading centres |
Language/logistics | English-speaking staff, no travel required for residents | Requires S2 medical visa, English-speaking coordinators at major international centres, longer stay abroad |
Insurance coverage | Partial coverage possible via some local insurers/riders | Rarely covered by Singapore insurers; typically self-funded |
Length of required stay | Usually manageable locally with follow-up visits | Often several weeks to a few months, including a mandatory post-infusion monitoring window |
Solid tumour trial access | Limited | Broader range of active solid tumour CAR-T trials |
The honest takeaway: Singapore offers convenience, continuity of care, and no language barrier. China offers substantially lower cost and, for some diagnoses, faster access and a wider range of trial options — at the cost of travel complexity, time away from home, and a support system that has to be built abroad.
How Singaporean Patients Can Access CAR-T Therapy in China
If you're seriously considering this path, here's what the process typically looks like:
Get your full diagnostic records in order. This includes bone marrow biopsy results, blood work, imaging, and a summary of all prior treatments. Chinese hospitals' international departments use this to determine eligibility before you travel.
Submit records for a preliminary eligibility review. Most major centres respond within 24–48 hours with an initial assessment of whether you qualify for a commercial product or a trial pathway.
Apply for an S2 medical visa once the hospital issues an invitation letter.
Travel for in-person evaluation, apheresis (T-cell collection), and — if eligible — proceed to lymphodepleting chemotherapy and infusion.
Plan for an extended stay, typically several weeks, to cover the manufacturing window plus a mandatory post-infusion monitoring period for side effects like cytokine release syndrome (CRS).
Arrange a travel companion. Almost every hospital and facilitator strongly recommends this, both for emotional support and practical help during the monitoring phase.
If cost is the deciding factor for your family, it's worth having a direct conversation with your Singapore-based haematology team about CAR-T treatment Singapore eligibility criteria first — sometimes a clinical trial slot locally can close the cost gap without requiring travel at all.
→ Read Full Guide: Medical Tourism in China 2026 for Southeast Asian Patients
Learn about treatment planning, travel logistics, costs, and patient support services for medical care in China.
Risks and Honest Questions to Ask Before Choosing Either Path
CAR-T therapy, wherever you receive it, carries real risks: cytokine release syndrome, neurotoxicity, and infection risk during the period when your immune system is rebuilding. These risks don't disappear because a treatment is cheaper — they need equally serious monitoring wherever you are.
Before committing to either country, ask:
What is my specific eligibility — has my cancer type and treatment history been reviewed by a specialist at this exact centre, not just a general estimate?
What happens if I experience severe CRS or neurotoxicity — does this hospital have ICU-level supportive care on-site?
What is the full, itemised cost — not just the headline number, but travel, accommodation, translation, and follow-up?
What is the realistic total time away from home, work, and family?
If something goes wrong, what does aftercare and long-term follow-up look like once I return to Singapore?
These aren't uncomfortable questions to avoid — they're the questions that protect you from a decision made on hope and marketing copy rather than facts.
Making the Right Choice for Your Situation
There's no universally "better" answer between CAR-T treatment in Singapore and CAR-T therapy in China — there's only the answer that fits your specific diagnosis, financial reality, and support system.
If cost isn't the primary constraint, Singapore's established programs at SGH, NUH, and NCCS offer continuity, no language barrier, and treatment close to home during an already exhausting time. If the price gap is the difference between accessing treatment at all versus not, China's growing CAR-T infrastructure — particularly its trial pathways — has become a legitimate, increasingly well-documented option for international patients.
Whichever direction you're leaning, the single most valuable next step is a direct conversation with your treating oncology team about your specific eligibility, timeline, and financial options. For a deeper look at what CAR-T eligibility and the local treatment pathway involves, see our full guide to:
→ Read Full Guide: CAR-T Therapy in China 2026 – Complete Treatment Guide, Costs & Top Options
Learn about CAR-T therapy, eligibility, treatment costs, top hospitals, and the patient journey in China.
How ChinaCureLink Bridges the Gap for Indonesian Patients
This is where a purpose-built medical facilitation service becomes essential. ChinaCureLink (powered by Medebound HEALTH ) specialises exclusively in connecting international patients — including Singaporean s — with China's leading oncology institutions.
About ChinaCureLink (Medebound HEALTH): Founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific. Contact us below for free medical record review.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Practical Considerations: Visa, Travel, and What to Bring
Medical Visa for Indonesia to China
Indonesian citizens are eligible to apply for a Chinese medical (M) visa when travelling for treatment at a recognised Chinese medical institution. Your facilitator will provide an invitation letter from the hospital — a required component of the visa application. Processing typically takes 5–10 business days.
Travel Time and Logistics
Direct flights from Singapore to Shanghai (PVG), Beijing (PEK), or Guangzhou (CAN) are available, with travel times of approximately 4–6 hours.
Accommodation near treatment centres ranges from international hotel chains to serviced apartments — your facilitator can recommend and book appropriate options.
A companion or carer accompanying the patient is strongly recommended, especially during the post-infusion monitoring period.
What to Bring
All available medical records (pathology, imaging, treatment history) in English — ideally certified copies
A complete medication list
Travel insurance documentation (note: standard travel insurance does not cover pre-existing cancer treatment; specialist medical travel insurance is available)
Power adapters (China uses Type A, C, and I plugs — Singaporean plugs are compatible with Type I sockets)
Translation apps and a VPN (social media and Google services are restricted in China)
Language Support
ChinaCureLink provides interpreter services throughout your hospital stay. Major oncology hospitals in Shanghai, Beijing, and Hangzhou also have international patient departments with English-speaking staff.
Frequently Asked Questions
Is CAR-T therapy available in Singapore?
Yes. Singapore has HSA-approved commercial CAR-T therapy for relapsed/refractory DLBCL and B-cell ALL, available at centres like Singapore General Hospital.
How much does CAR-T treatment cost in Singapore compared to China?
Singapore's total treatment cost is commonly estimated at US$200,000–300,000, while China's ranges from roughly US$40,000 (via eligible clinical trials) to US$170,000 (commercial products), though figures vary by source and hospital.
Do Singaporean insurers cover CAR-T therapy?
Coverage is inconsistent. Some insurers offer partial coverage under critical illness or cancer riders — always confirm directly with your insurer before assuming coverage.
Is CAR-T therapy in China safe for international patients?
Leading centres like PUMCH, Fudan Cancer Center, and Peking University Cancer Hospital have established international patient programs with English-language support, though quality and support infrastructure vary by hospital — thorough due diligence is essential.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top 5 cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team that understands both the medical and cultural needs of Southeast Asian patients.
ChinaCureLink is proudly affiliated with Medebound HEALTH— an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia Pacific, Medebound HEALTH brings the same standard of expert care coordination to every patient we serve.
Comments